TriangleNCT01522976 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Days
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 5 years
What was measured
OS is calculated for all patients from the date of initial registration to date of death due to any cause. The follow- up for patients last known to be alive is censored at the date of last contact. OS will be estimated for each of the three arms using the Kaplan-Meier method.
Analysis population: Analysis includes eligible patients only.
Groups in this outcome
Arm 1: Azacitidine/Lenalidomide
Patients receive azacitidine SC or IV on days 1-7 or days 1-5 and 8-9, and lenalidomide PO QD on days 1-21. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity. Azacitidine: Given SC or IV Lenalidomide: Given PO
Arm 2: Azacitidine
Patients receive azacitidine as in Arm 1. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity. Azacitidine: Given SC or IV
Arm 3: Azacitidine/Vorinostat
Patients receive azacitidine as in Arm 1 and vorinostat PO BID on days 3-9. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity. Azacitidine: Given SC or IV Vorinostat: Given PO
| Group | Source count |
|---|---|
| Arm 1: Azacitidine/Lenalidomide | 93 |
| Arm 2: Azacitidine | 92 |
| Arm 3: Azacitidine/Vorinostat | 92 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm 1: Azacitidine/Lenalidomide | 588 | Not reported | 426 | 737 | Not reported |
| Arm 2: Azacitidine | 449 | Not reported | 356 | 603 | Not reported |
| Arm 3: Azacitidine/Vorinostat | 527 | Not reported | 392 | 852 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 426
- upper Limit
- 737
- value
- 588
- group Id
- OG001
- lower Limit
- 356
- upper Limit
- 603
- value
- 449
- group Id
- OG002
- lower Limit
- 392
- upper Limit
- 852
- value
- 527
- denoms
- counts
- group Id
- OG000
- value
- 93
- group Id
- OG001
- value
- 92
- group Id
- OG002
- value
- 92
- units
- Participants
- description
- OS is calculated for all patients from the date of initial registration to date of death due to any cause. The follow- up for patients last known to be alive is censored at the date of last contact. OS will be estimated for each of the three arms using the Kaplan-Meier method.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive azacitidine SC or IV on days 1-7 or days 1-5 and 8-9, and lenalidomide PO QD on days 1-21. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity. Azacitidine: Given SC or IV Lenalidomide: Given PO
- id
- OG000
- title
- Arm 1: Azacitidine/Lenalidomide
- description
- Patients receive azacitidine as in Arm 1. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity. Azacitidine: Given SC or IV
- id
- OG001
- title
- Arm 2: Azacitidine
- description
- Patients receive azacitidine as in Arm 1 and vorinostat PO BID on days 3-9. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity. Azacitidine: Given SC or IV Vorinostat: Given PO
- id
- OG002
- title
- Arm 3: Azacitidine/Vorinostat
- param Type
- MEDIAN
- population Description
- Analysis includes eligible patients only.
- reporting Status
- POSTED
- time Frame
- Up to 5 years
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- Days
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice